ACRS — Aclaris Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $84.19m
- -$26.91m
- $31.25m
- 28
- 42
- 33
- 26
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -161 | -51 | -90.9 | -86.9 | -88.5 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 61.2 | 13.6 | 39.2 | 19.7 | 0.271 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -2.7 | -2.36 | -1.34 | -1.2 | 9.39 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -96.4 | -38.6 | -52.1 | -67.6 | -78.3 |
Capital Expenditures | -1.61 | -0.453 | -0.308 | -0.605 | -1.31 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 107 | 6.84 | -167 | 13.2 | 47.5 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 106 | 6.39 | -168 | 12.6 | 46.2 |
Financing Cash Flow Items | — | -0.211 | -3.12 | -0.034 | -0.102 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -30.3 | 18.4 | 225 | 72.9 | 26.7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -21.1 | -13.9 | 5.29 | 17.9 | -5.4 |